clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Parkinson Disease D010300 53 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Influenza, Human D007251 11 associated lipids
Lymphadenitis D008199 8 associated lipids
Drug Eruptions D003875 30 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Synovitis D013585 15 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bacteremia D016470 9 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Barrett Esophagus D001471 3 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Rosacea D012393 13 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Jaup BH and Norrby A Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7771426
Pamuk ON et al. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? 2000 Am. J. Gastroenterol. pmid:10926000
Schaeverbeke T et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. 2005 Am. J. Gastroenterol. pmid:16393213
de Bortoli N et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. 2007 Am. J. Gastroenterol. pmid:17313499
Mohar A et al. Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. 2002 Am. J. Gastroenterol. pmid:12385434
De Francesco V et al. Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? 2002 Am. J. Gastroenterol. pmid:12385470
Chey WD and Wong BC American College of Gastroenterology guideline on the management of Helicobacter pylori infection. 2007 Am. J. Gastroenterol. pmid:17608775
Uygun A et al. Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. 1999 Am. J. Gastroenterol. pmid:10520880
Cremonini F et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. 2002 Am. J. Gastroenterol. pmid:12425542
Peterson WL et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. 1993 Am. J. Gastroenterol. pmid:8237933
van Zanten SV and Thompson K Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? 2006 Am. J. Gastroenterol. pmid:16863548
Froehlich F et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. 2001 Am. J. Gastroenterol. pmid:11513170
Rokkas T et al. Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. 2006 Am. J. Gastroenterol. pmid:16928256
Lazzaroni M et al. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. 1997 Am. J. Gastroenterol. pmid:9128316
Sapone A et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. 2003 Am. J. Gastroenterol. pmid:12809821
Zhou L et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. 2014 Am. J. Gastroenterol. pmid:24642580
Sharma VK et al. A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. 1999 Am. J. Gastroenterol. pmid:10566709
Levy M et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. 2002 Am. J. Gastroenterol. pmid:11866264
Christopher K et al. Clarithromycin use preceding fulminant hepatic failure. 2002 Am. J. Gastroenterol. pmid:11866297
Gisbert JP et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. 2006 Am. J. Gastroenterol. pmid:16454825
Vakil N et al. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. 1998 Am. J. Gastroenterol. pmid:9732920
Chu KM et al. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. 1998 Am. J. Gastroenterol. pmid:9732921
Lamouliatte H et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. 1998 Am. J. Gastroenterol. pmid:9732938
Hsu PI et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. 2005 Am. J. Gastroenterol. pmid:16279889
Vakil N Helicobacter pylori: factors affecting eradication and recurrence. 2005 Am. J. Gastroenterol. pmid:16279890
Sullivan B et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:12385435
Gisbert JP et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. 2008 Am. J. Gastroenterol. pmid:17764498
Lerang F et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? 1997 Am. J. Gastroenterol. pmid:9040200
Chey WD et al. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. 1997 Am. J. Gastroenterol. pmid:9317068
Ozmen MM and Johnson CD Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? 1995 Am. J. Gastroenterol. pmid:7661197
Savarino V et al. New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 1995 Am. J. Gastroenterol. pmid:7717343
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Sirimontaporn N et al. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. 2010 Am. J. Gastroenterol. pmid:20010919
Basu PP et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. 2011 Am. J. Gastroenterol. pmid:21989146
Hasegawa T et al. Image of the month: Disseminated Nontuberculous Mycobacteriosis. 2015 Am. J. Gastroenterol. pmid:26673493
Schwartz H et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 Am. J. Gastroenterol. pmid:9576452
Santander C et al. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. 1996 Am. J. Gastroenterol. pmid:8759659
Tursi A et al. Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. 1996 Am. J. Gastroenterol. pmid:8759696
Jarbol DE et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. 2006 Am. J. Gastroenterol. pmid:16771937
Bytzer P Management of the dyspeptic patient: anything goes? 2006 Am. J. Gastroenterol. pmid:16771938
Manes G et al. Eradication of Helicobacter pylori and dosages of esomeprazole. 2006 Am. J. Gastroenterol. pmid:16771971
Laine L et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. 2000 Am. J. Gastroenterol. pmid:11151867
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Maconi G et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? 2001 Am. J. Gastroenterol. pmid:11232676
Parasakthi N and Goh KL Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. 1995 Am. J. Gastroenterol. pmid:7872306
Kadayifçi A et al. Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease. 1995 Am. J. Gastroenterol. pmid:7872307
Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. 2017 Am. J. Gastroenterol. pmid:28071659
Buchanan Keller K and Lemberg L Torsade. 2008 Am. J. Crit. Care pmid:18158394
Kapadia M et al. Invasive Streptomyces infections: six cases and literature review. 2007 Am. J. Clin. Pathol. pmid:17369139
Sauter C and Blum S Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. 2003 Am. J. Clin. Oncol. pmid:12576932
Hsu CH et al. The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients. 2006 Am. J. Chin. Med. pmid:17163582
Wang YC et al. In vitro activity of Impatiens balsamina L. against multiple antibiotic-resistant Helicobacter pylori. 2009 Am. J. Chin. Med. pmid:19655409
Jacobson TA Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. 2004 Am. J. Cardiol. pmid:15518608
Yang X et al. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. Am J Ther pmid:25923229
Feng L et al. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther pmid:25569598
McCarthy DM et al. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. 2003 Sep-Oct Am J Ther pmid:12975717
Chang NL et al. Clarithromycin-Induced Torsades de Pointes. Am J Ther pmid:25057773
Kurowski K et al. Clarithromycin-induced alterations in vaginal flora. 2000 Am J Ther pmid:11317173
Alkim H et al. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther pmid:26808355
Gupta AK and Moorman CT Nocardia nova infection after primary anterior cruciate ligament reconstruction with tibialis anterior allograft. 2010 Am J Sports Med pmid:20375367
Zeng M et al. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. 2011 Nov-Dec Am J Rhinol Allergy pmid:22185725
Tohnai A et al. Clarithromycin suppresses proliferation of rat nasal epithelium exposed to endotoxin. 1998 Nov-Dec Am J Rhinol pmid:9883303
Keicho N and Kudoh S Diffuse panbronchiolitis: role of macrolides in therapy. 2002 Am J Respir Med pmid:14720066
Darkes MJ and Perry CM Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. 2003 Am J Respir Med pmid:14720016
Abouesh A and Hobbs WR Clarithromycin-induced mania. 1998 Am J Psychiatry pmid:9812131
Brooks JO and Hoblyn JC Secondary mania in older adults. 2005 Am J Psychiatry pmid:16263839
Einarson A et al. A prospective controlled multicentre study of clarithromycin in pregnancy. 1998 Am J Perinatol pmid:9890248
Jacoby EB and Porter KB Helicobacter pylori infection and persistent hyperemesis gravidarum. 1999 Am J Perinatol pmid:10355915
Evans AK and Cunningham MJ Atypical mycobacterial cervicofacial lymphadenitis in children: a disease as old as mankind, yet a persistent challenge. 2005 Sep-Oct Am J Otolaryngol pmid:16137534
Hashisaki GT Update on macrolide antibiotics. 1995 May-Jun Am J Otolaryngol pmid:7661309
Lilley LL and Guanci R A dangerous combination. 1998 Am J Nurs pmid:9612423
Antibiotic gets FDA nod for MAC treatment. 1994 Am J Nurs pmid:8304386
Sonnenberg A et al. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. 1999 Am J Manag Care pmid:10345967
Hsu O et al. Decreased plasma efavirenz concentrations in a patient receiving rifabutin. 2010 Am J Health Syst Pharm pmid:20852162
Johnson TJ and Hedge DD Esomeprazole: a clinical review. 2002 Am J Health Syst Pharm pmid:12132559
Halpern MT et al. Cost-effectiveness of gemifloxacin: results from the GLOBE study. 2002 Am J Health Syst Pharm pmid:12132563
Chahine C et al. Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. 2001 Am J Health Syst Pharm pmid:11596697
Henneman A and Thornby KA Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics. 2012 Am J Health Syst Pharm pmid:22644980
Kaeser YA et al. Severe hypotension and bradycardia associated with verapamil and clarithromycin. 1998 Am J Health Syst Pharm pmid:9825040
Three new studies expand understanding of MAC therapy. 1996 Am J Health Syst Pharm pmid:8899122
Peloquin CA and Berning SE Advice on treatment of Mycobacterium avium complex infection. 1997 Am J Health Syst Pharm pmid:9161632
H. pylori treatment recognized by FDA. 1996 Am J Health Syst Pharm pmid:8725200
Sketris IS et al. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies. 2004 Am J Geriatr Pharmacother pmid:15555476
Yeh I et al. Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms. 2011 Am J Dermatopathol pmid:21712686
Song H et al. Cutaneous nontuberculous mycobacterial infection: a clinicopathological study of 7 cases. 2009 Am J Dermatopathol pmid:19384062
Lai J et al. Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. 2013 Am J Dermatopathol pmid:22935892
Elston D Nontuberculous mycobacterial skin infections: recognition and management. 2009 Am J Clin Dermatol pmid:19658440
Rebora A The management of rosacea. 2002 Am J Clin Dermatol pmid:12180896
Scheinfeld N Confluent and reticulated papillomatosis : a review of the literature. 2006 Am J Clin Dermatol pmid:17007541
Zeegelaar JE and Faber WR Imported tropical infectious ulcers in travelers. 2008 Am J Clin Dermatol pmid:18572973
Chang SL et al. Bilateral sporotrichoid lymphocutaneous dermatosis in a drug abuser: case report and review of the literature. 2008 Am J Clin Dermatol pmid:18973406
Wedi B and Kapp A Helicobacter pylori infection in skin diseases: a critical appraisal. 2002 Am J Clin Dermatol pmid:12010072
Curth HM et al. Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study. 2015 Am J Clin Dermatol pmid:26334425
Parsad D et al. A guide to selection and appropriate use of macrolides in skin infections. 2003 Am J Clin Dermatol pmid:12762831
Damianos AJ and McGarrity TJ Treatment strategies for Helicobacter pylori infection. 1997 Am Fam Physician pmid:9191460
Karlstadt RG and Walker K Update on prescribing information for pantoprazole. 2003 Am Fam Physician pmid:12674447
Gregory DS Pertussis: a disease affecting all ages. 2006 Am Fam Physician pmid:16913160
Chaisson R Clarithromycin is effective against M. avium complex in AIDS. 1992 Am Fam Physician pmid:1456199
Kim MH et al. A case of chlorpheniramine maleate-induced hypersensitivity with aspirin intolerance. 2011 Allergy Asthma Immunol Res pmid:21217928
Hong SJ The Role of Mycoplasma pneumoniae Infection in Asthma. 2012 Allergy Asthma Immunol Res pmid:22379599